- Conditions
- Spinal Cord Injuries
- Interventions
- 5HTP, L-DOPA, Placebo oral tablet, Carbidopa
- Drug
- Lead sponsor
- Jessica M D'Amico
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease
- Interventions
- carbidopa
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Dilworth, Minnesota
- Conditions
- Pregnancy Toxemia, Hypertension, Proteinuria
- Interventions
- methyldopa, labetalol, nifedipine, clonidine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type1 Diabetes
- Interventions
- 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- Drug
- Lead sponsor
- Immunomolecular Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Aurora, Colorado • Renton, Washington
- Conditions
- Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
- Interventions
- Droxidopa, Carbidopa, Entacapone
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- L-Histidine, Placebo, Lodosyn
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Autonomic Failure, Pure Autonomic Failure, Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies
- Interventions
- [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose
- Drug
- Lead sponsor
- Daniel Claassen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Dysautonomia, Familial, Baroreflex Failure Syndrome
- Interventions
- Carbidopa Low-Dose, Placebo, Carbidopa High-Dose
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
- Conditions
- Parkinsonian Signs in Older Persons
- Interventions
- carbidopa
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Parkinson Disease
- Interventions
- carbidopa/levodopa, as prescribed by treating physician
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Parkinson's Disease (PD)
- Interventions
- ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
- Interventions
- APOKYN, L-dopa, Trimethobenzamide
- Drug
- Lead sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
- Interventions
- Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
- Procedure · Device · Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Autonomic Failure, Orthostatic Hypotension
- Interventions
- Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Major Depressive Disorder, Dysthymia, Depression
- Interventions
- L-DOPA, Placebo Oral Tablet
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
- Interventions
- L-Dopa, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Parkinson's Disease
- Interventions
- XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
- Conditions
- Cocaine Abuse, Cocaine-Related Disorders
- Interventions
- Levodopa, Carbidopa, Clinical Management, Relapse Prevention Therapy, Contingency Management
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
- Interventions
- Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa
- Other · Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Parkinsonian Signs in Older Persons
- Interventions
- Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan
- Conditions
- Smoking
- Interventions
- CVT-301, Carbidopa
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas